Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Herzuma plus Gedatolisib in HER2-Positive Metastatic Breast Cancer
KCT0003727Phase 2Completed
- Sponsor
- Ministry of Health & Welfare
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab, gedatolisib in HER2-enriched breast cancer (HER2+), sponsored by Ministry of Health & Welfare. Started Dec 2019; status: completed.
02
Drugs
trastuzumabgedatolisib
03
Conditions
HER2-enriched breast cancer (HER2+)
Beyond the preview
Go deeper on KCT0003727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003727.